A cohort study of oral contraceptive use and risk of benign breast disease

International Journal of Cancer

Volumn 82, Issue 2, 1999, Pages 191-196

  Rohan, Thomas E ^a   Miller, Anthony B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST DISEASE; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SELF REPORT;

AMERICAS; BIOLOGY; CANADA; COHORT ANALYSIS; CONTRACEPTION; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; FAMILY PLANNING; MAMMARY GLAND EFFECTS; NORTH AMERICA; NORTHERN AMERICA; ORAL CONTRACEPTIVES; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; RISK FACTORS;

ADULT; BREAST DISEASES; CELL DIVISION; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; DIET; DRUG UTILIZATION; FEMALE; FIBROCYSTIC BREAST DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; LIFE STYLE; MASS SCREENING; MIDDLE AGED; ONTARIO; QUESTIONNAIRES; REPRODUCTIVE HISTORY; RISK; SMOKING;

EID: 0032975454     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990719)82:2<191::AID-IJC7>3.0.CO;2-F     Document Type: Article

References (34)

1. BERKOWITZ, G.S., KELSEY, J.L, LIVOLSI, V.A., HOLFORD, T.R., MERINO, M.J., ORT, S., O'CONNOR, T.Z., GOLDENBERG, I.S. and WHITE, C., Oral contraceptive use and fibrocystic breast disease among pre- and postmenopausal women. Amer. J. Epidemiol., 120, 87-96 (1984a).
2. BERKOWITZ, G.S., KELSEY, J.L., LIVOLSI, V.A., MERINO, M.J., HOLFORD, T.R., HILDRETH, N.G., ORT, S., O'CONNOR, T.Z. and WHITE, C., Exogenous hormone use and fibrocystic breast disease by histopathologic component. Int. J. Cancer, 34, 443-449 (1984b).
3. BODIAN, C.A., Benign breast diseases, carcinoma in situ, and breast cancer risk. Epidemiol. Rev., 15, 177-187 (1993).
4. BRINTON, L.A., VESSEY, M.P., FLAVEL, R. and YEATES, D., Risk factors for benign breast disease. Amer. J. Epidemiol., 113, 203-214 (1981).
5. CLINE, J.M., SODERQVIST, G., VON SCHOULTZ, E., SKOOG, L., and VON SCHOULTZ, B., Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Amer. J. Obstet. Gynecol. 174, 93-100 (1996).
6. COLE, P.T., Oral contraceptives and breast neoplasia. Cancer, 39, 1906-1908 (1977).
7. COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER, Breast cancer and hormonal contraceptives: collaborative reanalysis of data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet, 347, 1713-1727 (1996).
8. FRANCESCHI, S., LA VECCHIA, C., PARRAZINI, F., FASOLI, M., REGALLO, M., DECARLI, A., GALLUS, G. and TOGNONI, G., Oral contraceptives and benign breast disease: a case-control study. Amer. J. Obstet. Gynecol., 149, 602-606 (1984).
9. GOEHRING, C. and MORABIA, A., Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol. Rev., 19, 310-327 (1997).
10. HSIEH, C.-C., CROSSON, A.W., WALKER, A.M., TRAPIDO, E.J. and MACMAHON, B., Oral contraceptive use and fibrocystic breast disease of different histologic classifications. J. nat. Cancer Inst., 72, 285-290 (1984).
11. HUBER, P.J., The behaviour of maximum likelihood estimates under non-standard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Berkeley, University of California Press, 1, 221-233 (1967).
12. KAMPERT, J.B., WOOD, D.A. and PAFFENBARGER, R.S., Oral contraceptives and breast disease. In S.A. Feig and R. McLelland (eds.), Breast carcinoma: current diagnosis and treatment, pp. 597-607, Masson, Chicago (1983).
13. KELSEY, J.L., HOLFORD, T.R., WHITE, C., MAYER, E.S., KILTY, S.E. and ACHESON, R.M., Oral contraceptives and breast disease. Amer. J. Epidemiol., 107, 236-244 (1978).
14. KELSEY, J.L., LINDFORS, K.K. and WHITE, C., A case-control study of the epidemiology of benign breast diseases with reference to oral contraceptive use. Int. J. Epidemiol., 3, 333-340 (1974).
15. LEES, A.W., BURNS, P.E. and GRACE, M., Oral contraceptives and breast disease in premenopausal northern Albertan women. Int. J. Cancer, 22, 700-707 (1978).
16. LIVOLSI, V.A., STADEL, B.V., KELSEY, J.L, HOLFORD, T.R. and WHITE, C., Fibrocystic disease in oral-contraceptive users. N. Engl. J. Med., 299, 381-385 (1978).
17. MILLER, A.B., BAINES, C.J., TO, T. and WALL, C., Canadian National Breast Screening Study. I. Breast cancer detection and death rates among women aged 40 to 49 years. II. Breast cancer detection and death rates among women aged 50 to 59 years. Canad. med. Ass. J., 147, 1459-1488 (1992).
18. MILLER, A.B., HOWE, G.R., and WALL, C., The national study of breast cancer screening: protocol for a Canadian randomized controlled trial of screening for breast cancer in women. Clin. Invest. Med., 4, 227-258 (1981).
19. MILLER, F.R., SOULE, H.D., TAIT, L., PAULEY, R.J., WOLMAN, S.R., DAWSON, P.J. and HEPPNER, G.H., Xenograft model of progressive human proliferative breast disease. J. nat. Cancer Inst., 85, 1725-1732 (1993).
20. NOMURA, A. and COMSTOCK, G.W., Benign breast tumor and estrogenic hormones: a population-based retrospective study. Amer. J. Epidemiol., 103, 439-44 (1976).
21. ORY, H., COLE, P., MACMAHON, B. and HOOVER, R., Oral contraceptives and reduced risk of benign breast diseases. N. Engl. J. Med., 294, 419-422 (1976).
22. PAGE, D.L. and ANDERSON, T.J., Diagnostic histopathology of the breast, Churchill Livingstone, Edinburgh (1987).
23. PARAZZINI, F., LA VECCHIA, C., FRANCESCHI, S., DECARLI, A., GALLUS, G., REGALLO, M., LIBERATI, A. and TOGNONI, G., Risk factors for pathologically confirmed benign breast disease. Amer. J. Epidemiol., 120, 115-22 (1984).
24. PASTIDES, H., KELSEY, J.L., LIVOLSI, V.A., HOLFORD, T.R., FISCHER, D.B. and GOLDENBERG, I.S., Oral contraceptive use and fibrocystic breast disease with special reference to its hisopathology. J. nat. Cancer Inst., 71, 5-9 (1983).
25. PIKE, M.C., SPICER, D.V., DAHMOUSH, L. and PRESS, M.F., Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev., 15, 17-35 (1993).
26. PLU-BUREAU, G., LÊ, M.G., SITRUK-WARE, R., THALABARD, J.C. and MAUVAIS-JARVIS, P., Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Brit. J. Cancer, 70, 270-277 (1994).
27. RAUTALAHTI, M,. ALBANES, D., HAUKKA, J. and VIRTAMO, J., Risk factors for histologically confirmed benign breast tumors. Europ. J. Epidemiol., 10, 259-65 (1994).
28. RAVNIHAR, B., SEIGEL, D.G. and LINDTNER, J., An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Europ. J. Cancer, 15, 395-405 (1979).
29. ROHAN, T.E., L'ABBÉ, K.A. and COOK, M.G., Oral contraceptives and risk of benign proliferative epithelial disorders of the breast. Int. J. Cancer, 50, 891-894 (1992).
30. ROYAL COLLEGE OF GENERAL PRACTITIONERS, Oral contraceptives and health, pp. 25-26, Pitman Medical, London (1974).
31. ROYAL COLLEGE OF GENERAL PRACTITIONERS' ORAL CONTRACEPTION STUDY, Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet, i, 624 (1977).
32. SARTWELL, P.E., ARTHES, F.G. and TONASCIA, J.A., Epidemiology of benign breast lesions: lack of association with oral contraceptive use. N. Engl. J. Med., 288, 551-554 (1973).
33. VESSEY, M.P., DOLL, R. and SUTTON, P.M., Investigation of the possible relationship between oral contraceptives and benign and malignant breast disease. Cancer, 28, 1395-1399 (1971).
34. WREN, B., Hormonal replacement therapy and breast cancer. Eur. Menopause J., 2, 13-9 (1995).